Viridian Therapeutics (LTS:0K1R) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0K1R Viridian Therapeutics Inc LTS:0K1R
43 GF Score
Price $22.86
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Viridian Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0K1R
43GF Score
Viridian Therapeutics Inc LTS:0K1R
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viridian Therapeutics Business Description

Other Exchanges VRDN:USA1S1:Germany
Address 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
43GF Score

Get the complete analysis for LTS:0K1R

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.86
Price